GlobeNewsWire
14 Jun 2026, 23:30 UTC · 20w ago
Impact · against what's priced in
Ascentage Pharma's positive clinical updates for olverembatinib and lisaftoclax provide strong catalysts for growth. The data supports the expansion of olverembatinib into second-line CML treatment and validates Phase III results for Ph+ ALL, while optimizing dosing for lisaftoclax in CLL/SLL.
No priced-in read yet
What the story claims
5 claims · scored −1 bearish … +1 bullish
Olverembatinib demonstrated deep and durable responses in CML-CP patients resistant or intolerant to first-line TKI therapy, supporting its potential as a second-line treatment.
More positive than 92% of claims this week
Updated data from the Phase III POLARIS-1 study for olverembatinib in Ph+ ALL further validated its deep response rate and manageable safety profile.
Continue reading
5 related stories
The company provided critical updates including Phase III validation for olverembatinib in Ph+ ALL and evidence supporting its use as a second-line treatment for CML-CP.
Read from the article alone
No priced-in read yet
Clinical data presented at EHA2026 validates the therapeutic value of core assets, specifically showing encouraging results for the olverembatinib and lisaftoclax combination in pediatric patients.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 85% of claims this week
The combination of olverembatinib and lisaftoclax showed encouraging clinical data in pediatric patients with relapsed/refractory Ph+ ALL.
More positive than 76% of claims this week
Registrational Phase II data for lisaftoclax in CLL/SLL provided insights for optimizing individualized dosing regimens.
More positive than 61% of claims this week
Real-world data on lisaftoclax in myeloid neoplasms provided evidence of the drug's clinical utility.
More positive than 48% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company presented multiple positive clinical updates and robust efficacy data for its core assets at the EHA2026 Congress.
More positive than 87% of ticker scores this week
The company presented multiple positive clinical updates and robust efficacy data for its core assets at the EHA2026 Congress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
—
No price for AAPG right now — the quote feed didn't answer.
AAPG chart →—
No price for 6855 right now — the quote feed didn't answer.
6855 chart →
